Harshabad Singh
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Harshabad Singh as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:25 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07765836 · Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCMassachusetts General Hospital · not yet recruiting · Pancreatic Cancer Metastatic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Improving response prediction to neoadjuvant therapy in pancreatic cancerK08CA286749 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2023 to 2026 · $288,565 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:25 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.Clin Cancer Res · 202382 citationsRCR 6.7
- 39 citationsRCR 7.3
- Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.Cancer Immunol Res · 202430 citationsRCR 3.1
- 17 citationsRCR 4.9
- Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.JCO Precis Oncol · 20259 citationsRCR 1.8
- Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial.Eur J Nucl Med Mol Imaging · 20256 citationsRCR 2.3
- A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.J Gastrointest Cancer · 20252 citationsRCR 0.2